Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg Inhalation Solution Recalled by Nephron Pharmaceuticals Corp. Due to Lack of Assurance of Sterility; potential exposure to...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Nephron Pharmaceuticals Corp. directly.
Affected Products
Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg Inhalation Solution, packaged in 30x3 mL Sterile Unit-Dose Vials, a) 30 count (NDC 0487-0201-03) and b) 60 count (NDC 0487-0201-60) vials per carton, Rx only, Nephron Pharmaceutical Corporation, Orlando, FL
Quantity: a) 85,248 cartons and b) 35,292 cartons
Why Was This Recalled?
Lack of Assurance of Sterility; potential exposure to non-sterile lubricant during the filling process
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Nephron Pharmaceuticals Corp.
Nephron Pharmaceuticals Corp. has 10 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report